Abstract:Fengjiao Bu, 1, 2, &ast Yong-Soon Cho, 3, 4, &ast Qingfeng He, 1 Xiaowen Wang, 1 Saurav Howlader, 3, 4 Dong-Hyun Kim, 3, 4 Mingshe Zhu, 5 Jae Gook Shin, 3, 4 Xiaoqiang Xiang 1, 6 1 Department of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy, Fudan University, Shanghai, People's Republic of China; 2 Department of Pharmacy, Eye and ENT Hospital, Fudan University, Shanghai, People's Republic of China; 3 Department of Pharmacology and Pharmacogenomics Research Center, Inje University College of Medicine, Busan, Republic of Korea; 4 Center for Personalized Precision Medicine of Tuberculosis, Inje University College of Medicine, Busan, Republic of Korea; 5 Department of DMPK, MassDefect Technologies, Princeton, NJ, USA; 6 Department of Preclinical Evaluation, Quzhou Fudan Institute, Quzhou, Zhejiang Province, 324002, People's Republic of China &astThese authors contributed equally to this work Correspondence: Jae Gook Shin; Xiaoqiang Xiang, Email ; Background: Anlotinib was approved as a third line therapy for advanced non-small cell lung cancer in China. However, the impact of concurrent administration of various clinical drugs on the drug–drug interaction (DDI) potential of anlotinib remains undetermined. As such, this study aims to evaluate the DDI of anlotinib as a victim by establishing a physiologically based pharmacokinetic (PBPK) model. Methods: The PBPK model of anlotinib as a victim drug was constructed and validated in the Simcyp ® incorporating parameters derived from in vitro studies, pre-clinical investigations, and clinical research encompassing patients with cancer. Subsequently, plasma exposure of anlotinib in cancer patients was predicted for single- and multi-dose co-administration with typical perpetrators mentioned in Food and Drug Administration (FDA) industrial guidance. Results: Based on predictions, the CYP3A potent inhibitor ketoconazole demonstrated the most significant DDI with anlotinib, regardless of whether anlotinib is administered as a single dose or multiple doses. Ketoconazole increased the area under the concentration-time curve (AUC) and maximum concentration (C max ) of single-dose anlotinib to 1.41-fold and 1.08-fold, respectively. In contrast, rifampicin, a potent inducer of CYP3A enzymes, exhibited a relatively higher level of DDI, with AUC R and C maxR values of 0.44 and 0.79, respectively. Conclusion: Based on the PBPK modeling, there is a low risk of DDI between anlotinib and potent CYP3A/1A2 inhibitors, but caution and enhanced monitoring for adverse reactions are advised. To mitigate the risk of anti-tumor treatment failure, it is recommended to avoid concurrent use of strong CYP3A inducers. In conclusion, our study enhances understanding of anlotinib's interaction with medications, aiding scientists, prescribers, and drug labels in gauging the expected impact of CYP3A/1A2 modulators on anlotinib's pharmacokinetics. Keywords: anlotinib, DDIs, CYP3A, CYP1A2, PBPK Graphical According to the American Cancer Society's cancer statistics estimates, lung cancer remains the leading cause of cancer-related deaths in 2022, with 80–85% of cases being non-small cell lung cancer (NSCLC). 1,2 Conventional platinum-based chemotherapy regimens for NSCLC have limited efficacy, with a less than 5% 5-year survival rate. 3 Targeted therapies, particularly tyrosine kinase inhibitors (TKIs), provide new avenues for the management of NSCLC. Over the past decade, nearly 20 new TKIs have been approved by regulatory bodies, such as the European Medicines Agency and Food and Drug Administration (FDA). 1 Anlotinib, a recently developed small molecule multi-target TKI, has demonstrated efficacy in suppressing the activity of various receptors including vascular endothelial growth factor receptor, platelet-derived growth factor receptor, fibroblast growth factor receptor and c-Kit. The National Medical Products Administration (NMPA) granted its approval for the treatment of NSCLC in third-line therapy in 2018. Previous studies and drug package inserts have demonstrated that anlotinib exhibits non-substrate characteristics towards P-gp and is primarily metabolized by CYP1A2 and CYP3A4/5, with minor contributions from CYP2B6, CYP2C8, CYP2C9, CYP2C19, and CYP2D6. 4 The drug label cautions against concomitant administration with inhibitors and inducers of CYP1A2 and CYP3A4/5. 5 In our previous study, a PBPK model of anlotinib was established t -Abstract Truncated-

Application of Physiologically Based Pharmacokinetic Modelling for the Prediction of Drug–drug Interactions Involving Anlotinib As a Perpetrator of Cytochrome P450 Enzymes

Prediction of Pharmacokinetic Drug–Drug Interactions Involving Anlotinib as a Victim by Using Physiologically Based Pharmacokinetic Modeling

Prediction of Drug–Drug Interactions with Ensartinib As a Time-Dependent CYP3A Inhibitor Using Physiologically Based Pharmacokinetic Model

Application of Physiologically Based Pharmacokinetic Modeling to Evaluate the Drug–Drug and Drug–Disease Interactions of Apatinib

Modeling the complexity of drug-drug interactions: A physiologically-based pharmacokinetic study of Lenvatinib with Schisantherin A/Schisandrin A

Relative contributions of the major human CYP450 to the metabolism of icotinib and its implication in prediction of drug–drug interaction between icotinib and CYP3A4 inhibitors/inducers using physiologically based pharmacokinetic modeling

Potential Drug-Drug Interaction of Olverembatinib (HQP1351) Using Physiologically Based Pharmacokinetic Models

Early Prediction and Impact Assessment of CYP3A4-Related Drug-Drug Interactions for Small-Molecule Anticancer Drugs Using Human-CYP3A4-Transgenic Mouse Models

In Vitro Assessment of Inhibitory Effects of Kinase Inhibitors on CYP2C9, 3A and 1A2: Prediction of Drug-Drug Interaction Risk with Warfarin and Direct Oral Anticoagulants

Integration of transcriptomics and metabolomics reveals anlotinib-induced cytotoxicity in colon cancer cells

Physiologically based pharmacokinetic modeling of imatinib and N‐desmethyl imatinib for drug–drug interaction predictions

Pharmacokinetics and Disposition of Anlotinib, an Oral Tyrosine Kinase Inhibitor, in Experimental Animal Species

Evaluation of the drug–drug interaction potential of brigatinib using a physiologically‐based pharmacokinetic modeling approach

Potential risk of drug-drug interactions of ponatinib via inhibition against human UDP-glucuronosyltransferases

Docetaxel, cyclophosphamide, and epirubicin: application of PBPK modeling to gain new insights for drug-drug interactions

Quantitative prediction and clinical observation of a CYP3A inhibitor-based drug-drug interactions with MLN3897, a potent C-C chemokine receptor-1 antagonist

Understanding CYP3A4 and P‐gp mediated drug–drug interactions through PBPK modeling – Case example of pralsetinib

Comprehensive PBPK model to predict drug interaction potential of Zanubrutinib as a victim or perpetrator

Physiologically Based Pharmacokinetic Model Predictions of Panobinostat (LBH589) as a Victim and Perpetrator of Drug-Drug Interactions

Predict the Drug-Drug Interaction of a Novel PI3Kα/δ Inhibitor, TQ-B3525, and Its Two Metabolites Using Physiologically Based Pharmacokinetic Modeling

A novel model for the prediction of drug-drug interactions in humans based on in vitro cytochrome p450 phenotypic data